What Тафлотан Treats: Main Uses and Benefits

Тафлотан is principally used in the therapeutic domain of ocular hypotension to manage conditions characterized by chronically elevated intraocular pressure (IOP). The medication is indicated for reducing this pressure in patients diagnosed with Primary Open-Angle Glaucoma or Ocular Hypertension. This is generally applied across conditions involving functional stress where sustained IOP control is considered relevant, as IOP is a significant pathological risk factor.

---

Targeting Elevated Eye Pressure and Vision Protection

The primary therapeutic purpose is helping with the reduction of IOP, which may assist with reducing the potential for progressive optic nerve damage and supports the goal of maintaining the patient's existing visual field. The medicine plays a role in managing symptoms linked to organ-specific functional stress in clinical settings where chronic, unstable pressure patterns require attention. Тафлотан is relevant in situations requiring monotherapy or when additional symptomatic support is needed alongside other treatments.

Quick Fact: Relief for Chronic IOP This medicine is commonly used to help with long-term pressure management, rather than temporary, acute eye pain.

---

Easing the Burden of Chronic Treatment

The preservative-free formulation is applied in scenarios where additional management of discomfort is required, helping to address symptom clusters related to irritative states often caused by preservatives. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load, especially as symptoms interfere with routine activities.

Who Can and Cannot Use Тафлотан?

Eligibility for Тафлотан (Tafluprost) is strictly defined by regulatory documents, focusing on patient population, age, reproductive status, and pre-existing medical conditions.

---

Eligibility Scope

Classification	Status According to Regulatory Documents
Populations for Whom Use is Allowed	Adults (18 years and older) with Primary Open-Angle Glaucoma or Ocular Hypertension.
Populations for Whom Use is Contraindicated	Patients with known hypersensitivity to the active substance Tafluprost or any of the product’s excipients.
Populations for Whom Use is Not Recommended	Children and adolescents under 18 years; Pregnant or breastfeeding women.

---

Age, Pregnancy, and Conditional Rules

• Age-Related Eligibility: Use is not recommended for children and adolescents under 18 years, as safety and efficacy have not been established. No dosage alteration is needed for older adult patients.
• Pregnancy and Lactation Status: Use is not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus, and women of childbearing potential must use adequate contraception. Use is also not recommended while breastfeeding.
• Eligibility-Related Restrictions: Caution is required for patients with active intraocular inflammation (e.g., iritis/uveitis), as well as in aphakic patients or pseudophakic patients with a torn posterior lens capsule. Use with caution is also noted for patients with hepatic or renal impairment due to limited study data.

The official eligibility profile is structured around these classifications, explicitly defining which populations are restricted, contra-indicated, or require special caution based on documented evidence.

Interactions with other medicines and products

Official regulatory information primarily addresses the concurrent use of Tafluprost with other ophthalmic medications, as systemic interactions are not anticipated due to the drug’s extremely low systemic exposure.

Interaction Type	Interacting Substances & Regulatory Context
Prohibited Co-administration	Other Topical Prostaglandin Analogues (e.g., Latanoprost, Bimatoprost, Travoprost) are to be avoided. Co-administration of two or more ophthalmic prostaglandins may result in a paradoxical reduction of the IOP-lowering effect [FDA DailyMed].
Additive Effect	Topical Ophthalmic Beta-Blockers (e.g., Timolol) are documented to have an additive intraocular pressure (IOP) lowering effect when co-administered with Tafluprost [EMA SmPC].
Timing Requirement	Other Topical Ophthalmic Products must be administered at least 5 minutes apart. This separation is required to prevent drug washout and ensure product efficacy [FDA DailyMed].
Systemic Risk	Systemic Medicinal Products. No specific systemic interactions are anticipated or studied because systemic concentrations of Tafluprost following ocular dosing are extremely low [EMA SmPC].
Varied Effect	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Regulatory documents note conflicting reports on co-administration, suggesting that NSAIDs may either decrease or increase the IOP-lowering response of prostaglandin analogues.
Other Interactions	No specific interactions with food, alcohol, herbal products, or supplements are explicitly documented in official regulatory labels. No population-specific interaction cautions are noted in the labeling.

This structure reflects the regulatory focus on local drug-drug interactions within the ocular environment. The minimal systemic concentration achieved following administration dictates that the overall risk for pharmacokinetic interactions with systemic drugs is considered low.

Receptor Activation and Initial Signaling

The drug's active form (acid) is an agonist of specific Prostanoid FP receptors located in the ocular tissue. This molecular interaction initiates a cellular cascade by generating a signal that modifies the structure of the surrounding ocular tissue .

---

Increased Uveoscleral Fluid Drainage

The primary mechanistic effect involves increasing the aqueous humor outflow through the uveoscleral pathway (the non-traditional drainage route). By modulating the permeability and intercellular spacing within this route, the drug increases fluid conductance and removal.

---

⬇️ Physiological Pressure Adjustment

This increased fluid drainage through the uveoscleral pathway directly leads to a reduction in the total volume of aqueous humor inside the eye. This results in the physiological consequence of a decrease in intraocular pressure.

Tafluprost, marketed as Тафлотан, is an ophthalmic preparation containing the active substance at a concentration of 0.0015%. Its use follows a standardized protocol designed for long-term management of elevated intraocular pressure. This usage pattern emphasizes consistency and precision, defining the route, frequency, and maximum daily dose.

Administration Scope

Instruction	Detail
Route of Administration	The medication is for topical ocular use only, administered by instillation of one drop into the conjunctival sac of the affected eye(s).
Standard Dosing Regimen	The dose must not exceed once daily, as more frequent application may reduce the intended IOP-lowering effect. The standard strength used is the 0.0015% solution.
Dosing Schedule	The required frequency is once daily, with administration recommended consistently in the evening.
Missed Dose Protocol	If a scheduled dose is missed, the treatment should continue with the next scheduled dose at the usual time; doubling the dose is not permitted.

---

Procedural Conditions and Handling

Instruction	Detail
Single-Use Container Policy	The solution from the single-use container must be administered immediately after opening. Any residual solution must be discarded immediately to prevent contamination of the preservative-free formulation.
Co-administration Protocol	When used concomitantly with other topical ophthalmic products, a minimum interval of at least 5 minutes is required between the administration of each product.
Age-Group Guidance	No dosage adjustment is necessary for older adults. Use in pediatric patients (under 18 years) is not recommended due to a lack of established safety and efficacy data.

---

The usage framework establishes a fixed, controlled dosing protocol to maintain consistent therapeutic levels. This adherence to once-daily, single-drop application and specialized handling of the unit-dose containers is central to the product's administration guidelines.

Тафлотан: Recent Clinical Evidence

---

Evidence for Use in Primary Open-Angle Glaucoma and Ocular Hypertension

Clinical research for Тафлотан has largely centered on its use for Primary Open-Angle Glaucoma and Ocular Hypertension. The main research approach has involved multiple short- to medium-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies focused on measuring changes in the Intraocular Pressure (IOP) of adult patients, including those not previously controlled by other therapies. Studies reported patterns related to IOP measurements, specifically recording shifts in IOP levels from baseline across the observed populations. Research explored IOP levels in studies where the substance was observed alongside other active treatments.

---

Research on Specialized Glaucoma Contexts and Formulations

Research has also explored the use of the medicine in specialized patient groups, particularly those with Normal-Tension Glaucoma (NTG). This research involved long-term Observational and Retrospective Studies that spanned up to three years, examining changes in IOP and the progression of the Visual Field (VF). Additionally, studies have been conducted on the preservative-free formulation. These Switching Studies were designed to investigate measured changes in Ocular Surface Health indicators, such as corneal staining, and monitored patient-reported outcomes describing perceived discomfort. Research described that the IOP measurements were generally monitored following the change in formulation.

---

Long-Term Evidence and Areas of Research Uncertainty

Research has explored the longevity of the measurements associated with Тафлотан through extended observational studies, some following patients for up to three years. The evidence base for Тафлотан is characterized by high-quality RCTs for its primary study objective, but certain aspects remain uncertain. A key area where evidence is limited is the availability of long-term data tracking visual field progression, which is an important outcome assessed in glaucoma research. The long-term effects on the optic nerve are an area of continued research and monitoring through observational settings. Furthermore, data for certain groups remain insufficient, especially in the pediatric population.

Key Studies & References

1. Australian public assessment report for Tafluprost - Therapeutic Goods Administration (TGA)

Common questions about Тафлотан (FAQ)

Q: What is Тафлотан used for?

Тафлотан (Taflotan) is a brand name for tafluprost, a prostaglandin analog used as an eye drop medication. It is primarily prescribed to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By lowering pressure within the eye, it helps protect the optic nerve from damage and preserves vision.

Q: How does Тафлотан work to lower eye pressure?

Тафлотан works by increasing the outflow of aqueous humor (the clear fluid inside the eye) from the eye. It binds to specific receptors (prostaglandin F receptors) located in the eye, which facilitates the fluid draining through the uveoscleral pathway. This reduction in fluid accumulation effectively lowers the intraocular pressure.

Q: How should I use Тафлотан eye drops?

Тафлотан is typically administered as one drop into the affected eye(s) once daily, usually in the evening. It is important to follow your healthcare provider's specific instructions. If you use other eye drops, wait at least five minutes between applying Тафлотан and the other medication. Always wash your hands before use. Do not allow the dropper tip to touch your eye or any other surface to prevent contamination.

Q: What should I do if I miss a dose of Тафлотан?

If you miss a dose, you should apply the missed dose as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not use two doses at the same time to make up for a missed dose, as this could increase the risk of side effects.

Q: What are the common side effects of Тафлотан?

Common side effects associated with Тафлотан include:

• Eye irritation, such as stinging, burning, or itching.
• Redness of the eyes (conjunctival hyperemia).
• Changes in eyelash appearance, including increased length, thickness, and number.
• Eyelid changes.
• Changes in iris pigmentation, which may cause the eye color to become darker (usually brown).

If you experience severe or persistent side effects, contact your healthcare provider.

Q: Can Тафлотан change the color of my eyes?

Yes, Тафлотан can cause a gradual change in eye color, specifically by increasing the amount of brown pigment in the iris (the colored part of the eye). This change is often subtle, permanent, and usually noticeable after several months of use. It occurs most often in patients with mixed-color irides, such as blue-brown or green-brown. Discuss this with your eye care professional before starting treatment.

Storage and Disposal Requirements for Tafluprost Ophthalmic Solution

The storage requirements for Tafluprost are defined by two distinct phases, based strictly on official regulatory labeling.

Storage Conditions

Product State	Temperature Requirement	Duration / Constraint
Unopened Foil Pouches	Store in a refrigerator between 2 C to 8 C (36 F to 46 F).	Do not freeze.
After Opening Pouch	Store single-dose containers in the original foil pouch at room temperature, not exceeding 25 C (77 F).	Maximum 28 to 30 days.

Handling and Disposal

The preservative-free solution from an individual single-dose container must be discarded immediately after use; do not save remaining contents. All unused single-dose units remaining in an opened foil pouch must be thrown away after the 30-day limit. The medicine must be kept out of the sight and reach of children. Disposal of unused product or waste must follow local regulatory requirements and should not be thrown away via wastewater or household waste.